Akebia Therapeutics (AKBA) Amortization of Deferred Charges (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Amortization of Deferred Charges of $4.6 million for Q1 2026, down 26.8% year-over-year from $6.3 million in Q1 2025, and down 3.68% quarter-over-quarter from $4.8 million in Q4 2025.
Akebia Therapeutics (AKBA) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Amortization of Deferred Charges for 9 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 26.8% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $20.1 million (up 5.98% YoY), while the FY2025 annual figure was $21.8 million, up 66.87% from the prior year.
- Amortization of Deferred Charges declined to $4.6 million in Q1 2026 per AKBA's latest filing, from $4.8 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $7.2 million in Q3 2024 and bottomed at -$3.5 million in Q4 2023.
- Historically, Amortization of Deferred Charges has averaged $2.3 million across 5 years, with a median of $654000.0 in 2022.
- Annual changes were most pronounced in 2023 — Amortization of Deferred Charges sank 642.2% — and 2025, when it soared 6475.26%.
- Akebia Therapeutics' Amortization of Deferred Charges stood at $654000.0 in 2022, then tumbled by 642.2% to -$3.5 million in 2023, then jumped by 257.76% to $5.6 million in 2024, then fell by 15.05% to $4.8 million in 2025, then retreated by 3.68% to $4.6 million in 2026.
- Business Quant data shows AKBA's Amortization of Deferred Charges at $4.6 million in Q1 2026, $4.8 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.81 Mn |
| Jun 30, 2026 | 2.81 Mn |
| Mar 31, 2026 | 4.58 Mn |
| Mar 31, 2026 | 4.58 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | 6.18 Mn |
| Jun 30, 2025 | 6.18 Mn |
| Mar 31, 2025 | 6.25 Mn |
| Mar 31, 2025 | 6.25 Mn |
| Dec 31, 2024 | 5.59 Mn |
| Dec 31, 2024 | 5.59 Mn |
| Sep 30, 2024 | 7.25 Mn |
| Sep 30, 2024 | 7.25 Mn |
| Jun 30, 2024 | -97,000.00 |
| Jun 30, 2024 | -97,000.00 |
| Mar 31, 2024 | 326,000.00 |
| Mar 31, 2024 | 326,000.00 |